Arrowhead Pharmaceuticals (ARWR) said Tuesday it had filed a request for regulatory clearance to initiate a phase 1/2a clinical trial of its experimental therapy, ARO-ALK7, to treat obesity.
The company said the application was submitted to the New Zealand Medicines and Medical Devices Safety Authority for review.
It added pending approval, the company plans to evaluate the safety and tolerability of ARO-ALK7 in up to 90 adult volunteers with obesity.
The trial will consist of two parts, where the first part will assess single and multiple doses of ARO-ALK7 monotherapy, while the second part will evaluate ARO-ALK7 in combination with tirzepatide, an approved treatment for type 2 diabetes and weight management.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。